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Over half a million people in the United States have sys-
temic lupus. Most are women in their childbearing years.
They usually have arthritis and scarring rashes, and about
half have kidney involvement that may progress to renal
failure. With time, there is an increasing likelihood that the
brain will be involved, often resulting in loss of cognitive
ability, seizures, and psychosis. Although the clinical fea-
tures are highly variable, the patients are unified by the
 
constant presence of autoimmunity to nucleoproteins,
particularly to chromatin and small nuclear RNA-protein
particles such as the U series of snRNPs that mediate pre-
messenger RNA processing, and the Ro antigen (1). The
resulting autoantibodies account for much of the tissue in-
jury. For example, anti-DNA antibodies are harmful be-
cause they form immune complexes with extra cellular
DNA and trigger an Arthus type of tissue injury, and some-
times they cross-react with cell surface proteins to exert a
direct cytotoxic effect (2). Because of their central role in
 
pathogenesis as well as their diagnostic usefulness, much
effort has focused on understanding the mechanisms that
account for these autoantibodies (3).
Among many early clues, it was noted that IFN might
have pathogenic importance in lupus. For example IFN lev-
els are typically elevated in patients with lupus, and IFN ac-
celerates disease in NZB/W lupus mice (4, 5). Subsequently,
it became apparent that IFN treatment of patients with neo-
plastic and viral diseases regularly induces fever, lethargy, and
arthralgias much like the symptoms found among patients
with active lupus. Occasionally, these patients develop anti-
nuclear antibodies and a small number go on to express
 
overt lupus (6–8). Finally, it was reported that IFN-
 
 
 
 in sera
from patients with lupus causes monocytes to differentiate
into effective antigen presenting cells that are hypothesized
to enhance formation of autoreactive T cells (9).
 
This line of inquiry is extended now in two reports in this
issue. The paper by Santiago-Raber et al. demonstrates that
type I IFNs are essential for most of the autoimmune pheno-
type in NZB lupus mice (10). The paper by Bennett et al.
shows that peripheral blood mononuclear cells from pediat-
ric patients with lupus regularly have alterations in gene tran-
 
scription that are attributable to changes induced by IFN-
 
 
 
and the effects of accelerated granulopoiesis (11). Here, I will
suggest that the emerging insights concerning IFN-
 
 
 
, den-
dritic cell (DC) biology, and apoptosis provide a rationale for
autoimmunity in humans with lupus that is focused on nu-
cleoproteins. A mechanism is proposed in which DCs both
generate and respond to IFN-
 
 
 
 in a way that enhances pre-
sentation of selected nuclear constituents to T helper cells.
 
The NZB mouse strain studied by Santiago-Raber et al.
normally exhibits severe Coomb’s positive hemolytic ane-
mia, anti-DNA antibodies, and glomerulonephritis. This
group has now developed a transgenic strain of NZB mice
 
that lack the 
 
 
 
 chain of the IFN-
 
 
 
/
 
 
 
 receptor (12). They
report that these mice have a near normal phenotype with
very little hemolytic anemia, glomerulonephritis, or autoan-
tibody production compared with littermate controls. This
work makes it clear that type I IFNs have an essential role in
this mouse model of lupus. Similar work demonstrates that
IFN-
 
 
 
 determines the level of autoimmunity that develops
in C57/B6 lpr/lpr mice (13). It will be of interest to learn if
the same is true in other models such as NZB/W mice that
have a more severe lupus-like phenotype. Caution is war-
ranted in extrapolating directly from these mouse models to
human lupus, as signaling pathways for IFN differ to some
extent between mouse and man (14).
Direct evidence that IFN-
 
 
 
 is the principal cytokine af-
fecting peripheral blood mononuclear cells in lupus is pro-
vided by the study of Bennett et al. This group reports that
genes regulated by IFN-
 
 
 
 are up-regulated in pediatric pa-
tients with lupus. Interestingly, several of the augmented
genes encode for proteins that play direct roles in patho-
genesis and tissue injury in lupus such as one of the Ro au-
toantigens, two inhibitors of the complement cascade, and
several genes related to apoptosis. Conceivably the prod-
ucts of these genes contribute respectively to enhanced lev-
els of autoantigen, impaired clearance of immune com-
plexes, and altered sensitivity to cell death signals. Other
up-regulated genes encode proteins associated with DC
maturation such as DC-LAMP, TAP1, and CD83 consis-
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tent with the earlier finding that IFN-
 
 
 
 induces peripheral
blood monocytes to transform into myeloid DCs and pro-
motes their maturation (9). These studies were performed
on the complex mixture of cells in the peripheral blood.
The fact that the IFN signature is reproduced when PBMCs
are incubated in culture with IFN-
 
 
 
 argues strongly that
the changes observed in patients is caused by IFN-induced
alterations in gene transcription and is not secondary to
shifts in these cell populations.
A finding in this latter study that is likely to astonish
rheumatologists is the presence of a population of large
granular cells that bear phenotypic markers of immature
granulocytes. Apparently, these cells escaped our attention
previously. Perhaps, because many of them are so imma-
ture that nuclear condensation has not occurred, we have
mistaken them for monocytes. Possibly they are more
prominent among patients in the pediatric age group. Asso-
ciated with their presence, a number of genes related to
granulopoiesis are dramatically overexpressed. In contrast
to the IFN-
 
 
 
 signature, neither these genes nor the large
granular cells themselves are responsive to treatment with
corticosteroids. It is unclear if and how these cells partici-
pate in the pathophysiology of lupus, and further informa-
tion about the mechanisms that drive their production is
needed. In any case at least, enhanced turnover of granulo-
cytes is likely to add to the burden of material that must be
cleared by phagocytic cells.
 
Generation of IFN in Lupus.
 
The two studies discussed
here imply that excessive amounts of IFN 
 
 
 
 are reliably
produced in lupus and that this cytokine could have a pow-
erful effect on determining the disease process. But what
might the source be? We know that IFN is produced by a
wide variety of cells and secreted in response to viral and
bacterial infection. Plasmacytoid DCs stand out as a major
possibility because of their capacity to produce unusually
large amounts of this cytokine (15–17). These cells secrete
IFN-
 
 
 
 in response to viral infections and when exposed to
sera of patients with lupus (18).
Recent data indicate that DNA-anti-DNA complexes in
lupus sera can provide an activation signal for IFN 
 
 
 
 secre-
tion through the toll-like receptor (TLR) 9, the same TLR
that responds to bacterial DNA sequences containing non-
methylated CpG motifs (19, 20). There are two limitations
here. First, the DNA motifs that can trigger TLR 9 are
characteristic of bacterial DNA but relatively uncommon
in the mammalian genome, and what is there, is usually
methylated so that it does not trigger the receptor. Second,
the immune complexes from lupus sera require both the
DNA and the Fc component of the anti-DNA antibody
but there is scant evidence that plasmacytoid DCs express
the types of Fc receptors that sensitize cells to activation.
Possibly the complexes from lupus sera contain DNA frag-
ments of bacterial or viral origin or the antibody somehow
enriches nonmethylated CpG motifs from mammalian
DNA as it resides in the extra cellular environment. More-
over, immune complexes in lupus sera may trigger other
so-called myeloid DCs or other cells to produce IFN-
 
 
 
. It
is noteworthy also that immune complexes containing
DNA activate B cells by cross-linking the B cell antigen re-
ceptor with TLR 9 (21). It remains to be determined if this
activation is associated with IFN-
 
 
 
 secretion. Finally, im-
mune complexes containing small RNAs such as the Ro
RNAs potentially activate toll 3 receptors that are ex-
pressed on myeloid DCs since these RNAs have a double
stranded structure that might mimic the double stranded
viral RNAs normally recognized by this receptor. Quite
possibly several of the mechanisms mentioned above are
operative within individual patients with active lupus.
 
DCs in Lupus.
 
It has recently become evident that DCs
can play a pivotal role in determining the balance between
responsiveness and tolerance in the immune system in an
antigen specific manner (22). One proposal is that imma-
ture DCs constantly circulate through the tissues of the
body and load themselves with “self” molecules and other
harmless environmental substances. Upon interaction with
T cells, they deliver a signal that results in the deletion, an-
ergy and/or regulation of cells that recognize the material
they carry. This ability has been established most clearly for
the so-called myeloid lineage of DCs (22–24). It remains to
be determined whether DCs derived from monocytes ever
have a phase during which they are able to tolerize T cells.
It is clear however, that these cells are potent stimulators of
naive T cells (9).
It is not surprising that cells with these abilities should at-
tract the attention of investigators interested in lupus (15).
Thus far, what has been learned includes the fact that so
called myeloid DCs in blood tend to be reduced in number
but fluctuate widely over time in individual patients (25). In
contrast, plasmacytoid DCs are more consistently reduced
in the circulation, presumably because they have become
activated and migrated into peripheral lymphoid tissues and
sites of inflammation. In fact, they have been observed to
accumulate in lupus skin lesions and nasal mucosa of pa-
tients with allergies (26, 27). One study reports that lupus
monocytes have a deficit in differentiation into DCs but the
significance of this observation remains unclear (28). An im-
portant finding in mice, is that overexpression of CD40L in
the basal layers of the epidermis accelerates DC maturation
and migration to regional lymph nodes (29). The result is
severe dermatitis with both T cell and B cell autoimmunity
to local skin antigens and humoral autoimmune responses to
nuclear antigens including DNA. This model supports the
idea that chronic DC activation leads to autoimmunity and
demonstrates that the antigens they deliver to T cells corre-
spond to the site of activation. The fact that DC maturation
signals in the skin induce autoimmunity to DNA as well as
to local skin-specific antigens likely reflects the wide spread
availability of chromatin throughout the bodies tissues.
Along this line, DCs that have ingested apoptotic cells in
culture induce antinuclear antibodies in BALB/c mice and
accelerate autoimmunity in NZB/W mice (30). Also, the
autologous mixed lymphocyte response by T cells appears
to be largely dependent upon DCs presenting antigens de-
rived from apoptotic elements (31, 32). Taken together,
these observations indicate that chronic activation of DCs
induces immune responses to nucleoproteins in mice. TheyT
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are in line with observations in humans that antinuclear an-
tibodies frequently accompany a broad range of chronic in-
fectious diseases where DC maturation is likely to occur.
 
Setting the Focus on Nucleoproteins.
 
The work of Rosen
et al. indicate that many of the lupus autoantigens are early
targets for caspase digestion and are selectively incorporated
into blebs on apoptotic cells (33). This material induces an-
tinuclear antibodies when injected into several different
strains of mice (34), presumably because it is processed and
presented to T cells by immunostimulatory DCs. This
mechanism is likely to account for T cell priming. The
question then is how does the process surmount tolerance
barriers in the B cell compartment. Perhaps an important
clue is that in a number of cases, early and possibly initial B
cell responses in both lupus prone mice and patients are di-
rected against epitopes that exist only on intact nucleopro-
tein particles such as the interface structures of histone
H2A-H2B (35–37). Presumably, such complex structures
are labile and have little ability to tolerize B cells within the
bone marrow. This concept accounts for a population of
autoreactive B cells that need only T cell help to respond
and to utilize epitope spreading and hypermutation mecha-
nisms to generate the broad array of autoantibodies to nu-
cleoproteins that mediate the disease.
Whether or not lupus results from these DC–T cell and
T cell–B cell interactions is clearly determined genetically.
For example, in mice over 35 different single gene muta-
tions are associated with a lupus phenotype that always in-
cludes the presence of antinuclear and anti-chromatin anti-
bodies (38). Many of these genes encode proteins that
regulate apoptosis, determine clearance of apoptotic cells,
or involve mechanisms of negative selection in central tol-
erance (39). For example, mice deficient in the gene en-
coding 
 
mer
 
, a receptor on macrophages required for up-
take of apoptotic cells, develop systemic autoimmunity that
includes production of antibodies to nuclear autoantigens.
Presumably, impaired macrophage clearance of cellular de-
bris enhances the amount of apoptotic material that is
loaded into DCs and possibly augments the amount of ma-
terial that can stimulate DC maturation. Single gene muta-
tions in humans and mice that are consistently associated
with lupus include defects in the early complement com-
Figure 1. Hypothetical model
for the role of IFN-  in propa-
gating autoimmunity to chroma-
tin. An exogenous event such as
a viral infection triggers IFN- 
secretion, thus simultaneously
augmenting apoptosis, monocyte
maturation, and T cell priming.
In an individual with a permis-
sive genetic make-up, T cell re-
sponses to chromatin compo-
nents such as histones are
induced providing the necessary
help for specific B cell responses
to components such as DNA.
Once initiated, the response is
perpetuated endogenously by the
ability of immune complexes
based on anti-DNA antibodies
(and possibly other specificities)
to stimulate secretion of IFN- 
by plasmacytoid DCs. Cell in-
jury secondary to these com-
plexes results in apoptotic cell
debris that contributes to en-
hanced loading of nucleoproteins
into DCs. Accelerated granu-
lopoiesis may contribute to the
burden of this material and rep-
resent an important source of
nucleoprotein autoantigens as
these cells turn over.T
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ponents, most notably C1q (40) and possibly DNase I (41).
Both are examples of gene defects that probably augment
the exposure of DCs to nuclear autoantigens through up-
take of immune complexes. However, in most patients
with lupus and in several classical animal models such as
NZB/W mice, multiple genes interact to create a predispo-
sition for the disease (42). Presumably these genes act in
concert to achieve an effect on T and B cell signaling and
autoantigen presentation that equates with the single gene
defects discussed above.
 
Perpetuating the Response.
 
These considerations suggest
a pathway that can account for immune responses to nucle-
oproteins, as illustrated in Fig. 1. Any event that triggers se-
cretion of excessive amounts of IFN-
 
 
 
 such as infection
and UV skin injury (known activators of lupus [43]), can
set the process in motion. The resulting IFN-
 
 
 
 promotes
the differentiation of monocytes into immunostimulatory
DCs as shown earlier (9). This process is likely to be en-
hanced by immune complexes delivering sensitizing signals
through FcRIII receptors on these cells (44, 45) and ge-
netic alterations that increase the flux of chromatin into
DCs as mentioned above. Other cytokines such as TNF-
 
 
 
are also involved as well. The augmentation of matured
DCs presenting nucleoprotein peptides now favors priming
of naive T cells and potentially impairs generation of T reg-
ulatory and T suppressor cells. In any event, the T cell help
required to support autoreactive B cells is now available
and the latter generate the immune complexes that appear
to trigger IFN-
 
 
 
 secretion. This process may require an in-
crease in the source of apoptotic cells or a reduction in
macrophage clearance of these cells. Tissue injury from im-
mune complexes and cytotoxic T cells is one source. It is
tempting also to speculate that rapid turnover of polymor-
phonuclear leukocytes in lupus, as implied by the finding of
excessive numbers of early granulocyte forms in the study
by Bennett and colleagues, represents another that might
serve to perpetuate the disease.
 
Opportunities for Intervention.
 
This scheme suggests sev-
eral therapeutic strategies to interrupt this vicious cycle.
They include blockade of IFN-
 
 
 
 either by preventing its
secretion from specific cell sources or by neutralization in
the extra cellular environment. Benefit may also be
achieved by enhancing destruction of nuclear autoantigens
with agents such as DNase I as well as strategies that aug-
ment macrophage scavenging. It may also be possible to
find ways to regulate DC maturation to limit excessive
stimulation of autoreactive T cells.
The model presented here rationalizes the occurrence of
antinuclear antibodies in many settings when DCs are called
upon for immune defenses and develops a hypothesis for
how this process might be propagated in individuals with
permissive genetic backgrounds. It also suggests that the
elusive trigger for lupus that has been so widely anticipated
may often be any factor that can generate sufficient IFN-
 
 
 
to set the disease in motion. We must be cautious as we
harness an increasing number of cytokines for therapeutic
purposes because these molecules play such an important
role in balancing self-tolerance and immune protection.
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